Objective To assess the incremental cost and cost-effectiveness of continuous and discontinuous regimens of bevacizumab (Avastin) and ranibizumab (Lucentis) for neovascular age-related macular ...
The team enrolled 19 patients over age 50 with advanced wet AMD and divided subjects into five groups that received different doses of the gene. “Even at the highest dose, the treatment was quite safe ...